Quarry LP’s Contineum Therapeutics CTNM Stock Holding History

Quarry LP’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Buy	25,073 +9,073	+57%	+$119K	0.03%	187
2026 Q1	$209K	Buy	+16,000	New	+$215K	0.04%	321

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quarry LP's CTNM Position: Q2 2026 in Review

Quarry LP increased its Contineum Therapeutics (CTNM) stake by 57% in Q2 2026, buying an estimated $119K and bringing the position to 25,073 shares worth $411K. The position accounts for 0.03% of the portfolio, ranked #187.

Quarry LP first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Quarry LP held 25,073 shares of Contineum Therapeutics worth $411K as of Q2 2026.
Quarry LP bought 9,073 Contineum Therapeutics shares in Q2 2026, an estimated $119K.
Contineum Therapeutics made up 0.03% of Quarry LP's portfolio in Q2 2026, its #187 holding.
Quarry LP first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.